Legend Biotech Corp Other Income
Legend Biotech Corp (LEGN) reported Other Income of $63.71 million for the 12-month period ending 2024-12-31, per its 20-F filed 2025-03-11.
Financial Statements › Income Statement › Other Income
ifrs-full:OtherIncome · last filed 2025-03-11
- Legend Biotech Corp other income for the quarter ending 2024-12-31 was $14.58M, a 22.20% decline year-over-year.
- Legend Biotech Corp other income for the quarter ending 2024-09-30 was $17.02M, a 8.50% decline year-over-year.
- Legend Biotech Corp other income for the quarter ending 2024-06-30 was $17.52M, a 38.79% increase year-over-year.
- Legend Biotech Corp other income for the quarter ending 2024-03-31 was $14.59M, a 94.64% increase year-over-year.
| Period end | Other Income 3 month | Other Income 6 month | Other Income 9 month | Other Income 12 month | Other Income 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $14.58M derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | $31.60M derived: sum of 2 quarters · filed 2025-03-11 | $49.12M derived: sum of 3 quarters · filed 2025-03-11 | $63.71M 20-F · filed 2025-03-11 | |
| 2024-09-30 | $17.02M derived: 6-K 9 month − 6-K 6 month · filed 2024-11-12 | $34.54M derived: sum of 2 quarters · filed 2024-11-12 | $49.13M 6-K · filed 2024-11-12 | $67.87M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2024-06-30 | $17.52M derived: 6-K 6 month − 6-K 3 month · filed 2024-08-09 | $32.11M 6-K · filed 2024-08-09 | $50.86M derived: sum of 3 quarters · filed 2025-03-11 | $69.45M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2024-03-31 | $14.59M 6-K · filed 2024-05-13 | $33.33M derived: sum of 2 quarters · filed 2025-03-11 | $51.93M derived: sum of 3 quarters · filed 2025-03-11 | $64.56M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-12-31 | $18.75M derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | $37.34M derived: sum of 2 quarters · filed 2025-03-11 | $49.97M derived: sum of 3 quarters · filed 2025-03-11 | $57.46M 20-F · filed 2025-03-11 | |
| 2023-09-30 | $18.60M derived: 6-K 9 month − 6-K 6 month · filed 2024-11-12 | $31.22M derived: sum of 2 quarters · filed 2024-11-12 | $38.72M 6-K · filed 2024-11-12 | $44.97M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-06-30 | $12.63M derived: 6-K 6 month − 6-K 3 month · filed 2024-08-09 | $20.12M 6-K · filed 2024-08-09 | $26.38M derived: sum of 3 quarters · filed 2025-03-11 | $28.11M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-03-31 | $7.49M 6-K · filed 2024-05-13 | $13.75M derived: sum of 2 quarters · filed 2025-03-11 | $15.48M derived: sum of 3 quarters · filed 2025-03-11 | ||
| 2022-12-31 | $6.25M derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | $7.99M derived: sum of 2 quarters · filed 2025-03-11 | $10.70M 20-F · filed 2025-03-11 | ||
| 2022-09-30 | $1.73M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-20 | $4.45M 6-K · filed 2023-11-20 | |||
| 2022-06-30 | $2.72M 6-K · filed 2023-08-15 | ||||
| 2021-12-31 | $2.74M 20-F · filed 2024-03-19 | $3.06M 20-F · filed 2022-03-31 | |||
| 2021-06-30 | $2.39M 6-K · filed 2021-08-23 | ||||
| 2020-12-31 | $6.01M 20-F · filed 2023-03-30 | $6.12M 20-F · filed 2021-04-02 | |||
| 2020-06-30 | $3.80M 6-K · filed 2021-08-23 | ||||
| 2019-12-31 | $7.46M 20-F/A · filed 2023-02-17 | $7.13M 20-F · filed 2021-04-02 | |||
| 2018-12-31 | $13.90M 20-F · filed 2021-04-02 |